Tilmodil 300 mg/ml, soultion for injection

Main information

  • Trade name:
  • Tilmodil 300 mg/ml, soultion for injection
  • Pharmaceutical form:
  • Solution for injection
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Tilmodil 300 mg/ml, soultion for injection
    United Kingdom
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • tilmicosin
  • Therapeutic area:
  • Cattle, Sheep

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0348/001
  • Authorization date:
  • 26-01-2011
  • EU code:
  • UK/V/0348/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

1.NAMEoftheveterinarymedicinalproduct:

TILMODIL300mg/mlSolutionforInjectionforcattleandsheep

2.QUALITATIVEandQUANTITATIVECOMPOSITION:

Activeingredient:Tilmicosin300 mg/ml

Excipient:Propyleneglycol250 mg/ml

Forafulllistofexcipients,seesection6.1.

3.PHARMACEUTICALFORM:

Solutionforinjection.

Clear,yellowishtobrown-yellowishsolution(pH=6).

4.CLINICALPARTICULARS:

4.1.Targetspecies:

Cattleandsheep.

4.2.Indicationsforuse:

TILMODILisindicatedforthetreatmentofpneumoniaincattleandsheep,associatedwithMannheimia

haemolytica,Pasteurellamultocidaandothermicroorganismssensitivetotilmicosin,andforthe

treatmentofovinemastitisassociatedwithStaphylococcusaureusandMycoplasmaagalactiae.

Forthetreatmentofinterdigitalnecrobacillosisincattle(bovinepododermatitis,foulinthefoot)and

ovinefootrot.

4.3.Contra-indications:

Donotadministerintravenously.

Donotadministertopigs.

Donotadministertohorses.

Donotadministertogoats.

4.4.Specialwarningsforeachtargetspecies:

Sheep:Donotinjectlambsweighinglessthan15kg,sincethereisarealriskofoverdosetoxicity.

Accurateweighingoflambsisimportanttoavoidoverdosage.Theuseofa2mlorsmallersyringewill

facilitateaccuratedosing.

4.5Specialprecautionsforuse:

i)Specialprecautionsforuseinanimals:

Official,nationalandregionalantimicrobialpoliciesshouldbetakenintoaccountwhentheproductis

used.

ii)Specialprecautionstobetakenbythepersonadministeringthemedicinalproducttoanimals:

OperatorSafetyWarnings:

Injectionofthisdruginhumanscanbelethal–Exerciseextremecautiontoavoidaccidentalself-

injectionandfollowtheadministrationinstructionsandtheguidancebelowprecisely

Thisproductshouldonlybeadministeredbyaveterinarysurgeon.

NevercarryasyringeloadedwithTilmodilwiththeneedleattached.Theneedleshouldbe

connectedtothesyringeonlywhenfillingthesyringeoradministeringtheinjection.Keepthe

syringeandneedleseparateatallothertimes.

Donotuseautomaticinjectionequipment.

Ensurethatanimalsareproperlyrestrained,includingthoseinthevicinity.

DonotworkalonewhenusingTilmodil.

IncaseofhumaninjectionSEEKIMMEDIATEMEDICALATTENTIONandtakethevialorthe

packageinsertwithyou.Applyacoldpack(noticedirectly)totheinjectionsite.

Additionaloperatorsafetywarnings:

Avoidcontactwitheyes.

Maycausesensitisationbyskincontact.Washhandsafteruse.

NOTETOTHEPHYSICIAN

Injectionoftilmicosininhumanshasbeenassociatedwithfatalities.

Thecardiovascularsystemisthetargetoftoxicity,andthistoxicitymaybeduetocalciumchannel

blockade.Administrationofintravenouscalciumchlorideshouldonlybeconsideredifthereis

positiveconfirmationofexposuretotilmicosin.

Indogstudies,tilmicosininducedanegativeinotropiceffectwithconsequenttachycardia,anda

reductioninsystemicarterialbloodpressureandarterialpulsepressure.

Donotgiveadrenalinorbeta-adrenergicantagonistssuchaspropranolol.

Inpigs,tilmicosin-inducedlethalityispotentiatedbyadrenaline.

Indogs,treatmentwithintravenouscalciumchlorideshowedapositiveeffectontheleftventricular

inotropicstateandsomeimprovementsinvascularbloodpressureandtachycardia.

Pre-clinicaldataandanisolatedclinicalreportsuggestthatcalciumchlorideinfusionmayhelpto

reversetilmicosin-inducedchangesinbloodpressureandheartrateinhumans.

Administrationofdobutamineshouldalsobeconsideredduetoitspositiveinotropiceffectsalthough

itdoesnotinfluencetachycardia.

Astilmicosinpersistsintissuesforseveraldays,thecardiovascularsystemshouldbeclosely

monitoredandsupportivetreatmentprovided.

Physicianstreatingpatientsexposedtothiscompoundareadvisedtodiscussclinicalmanagementwith

theNationalPoisonInformationServiceon: [Tocompletewithemergencytelephonenumberof

NationalPoisonInformationService(s).]

UK:08448920111;Ireland:018379964;Germany:03019240;Belgium,Luxembourg:070245

245;TheNetherlands:0302748888;Denmark:035315555

4.6Adversereactions(frequencyandseriousness):

Occasionally,asoftdiffuseswellingmayoccurattheinjectionsitebutthisdisappearswithinfivetoeight

days.

Deathsofcattlehavebeenobservedfollowingasingleintravenousdoseof5mg/kg,andfollowingthe

subcutaneousinjectionofdosesof150mg/kgat72hourintervals.Inpigs,intramuscularinjectionat

20mg/kghascauseddeaths.Sheephavediedfollowingasingleintravenousinjectionof7.5mg/kg.

4.7 Useduringpregnancy,lactationorlay:

Seesection4.11.

4.8 Interactionwithothermedicinalproductsandotherformsofinteraction:

Interactionsbetweenmacrolidesandionophoreshavebeenobservedinsomespecies.

4.9 Amounttobeadministeredandadministrationroute:

Asinglesubcutaneousinjectionof0.5or1mlTilmodilper30kgbodyweightincattleandsheep(eq.to

5or10mgtilmicosinperkg,respectively).

Cattle

Forpneumoniaincattle,use10mg/kgbodyweight.

Forinterdigitalnecrobacillosisincattle,use5mg/kgbodyweight.

Withdrawtherequireddosefromthevialandremovethesyringefromtheneedle.Ifagroupofanimalsis

tobetreated,leavetheneedleinthevialasadraw-offneedleforsubsequentdoses.Restraintheanimal

andinsertaseparateneedlesubcutaneouslyintotheinjectionsite.Injectioninafoldofskinovertherib

cagebehindtheshoulderissuggested.Connectthesyringetotheneedleandinjectintothebaseofthe

skinfold.Donotinjectmorethan20mlperinjectionsite.

Sheep

Withdrawtherequireddosefromthevialandremovethesyringefromtheneedle,leavingtheneedlein

thevial.Restrainthesheepwhilstleaningovertheanimalandinsertaseparateneedlesubcutaneously

intotheinjectionsite,whichshouldbeinafoldofskinovertheribcagebehindtheshoulder.Connect

thesyringetotheneedleandinjectintothebaseoftheskinfold.Usethesamedraw-offneedleforthe

wholegrouptobetreated.

Forpneumoniaandmastitisinsheep,use10mg/kgbodyweight.Donotinjectlambsweighinglessthan

15kg,sincethereisarealriskofoverdosagetoxicity.

Forthetreatmentoffootrot,use5mg/kgbodyweight.Duetothepotentialofinaccuratedosingleading

tooverdosing,thisproductshouldnotbeusedtotreatfootrotinsheepweighinglessthan30kg.

Accurateweighingoflambsisimportanttoavoidoverdosage.Theuseofa2mlorsmallersyringewill

facilitateaccuratedosing.

Avoidintroductionofcontaminationintobottleduringuse.Shouldanygrowthordiscolourationoccur

theproductshouldbediscarded.

Donotbroachthevialmorethan25times.

Ifnoimprovementisnotedwithin48hours,thediagnosisshouldbeconfirmed.

4.10. Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary:

Theacutemanifestationsofmultipleinjectionsoflargesubcutaneousdoses(150mg/kg)incattle

includedmoderateelectrocardiographicchangesaccompaniedbymildfocalmyocardialnecrosis,marked

injectionsiteoedema,anddeath.

Singlesubcutaneousinjectionsof30mg/kginsheepproducedincreasedrespirationrate,andathigher

levels(150mg/kg)ataxia,lethargyanddroopingofthehead.

4.11. Withdrawalperiods:

Cattletissues60days

Sheeptissues:42days.

Sheepmilk:15days(360hours).

Donotuseincattleproducingmilkforhumanconsumption.

Donotuseinpregnantdairyheifersordrydairycowswithin60daysofcalving.

5)PHARMACOLOGICALPROPERTIES:

Pharmcotherapeuticgroup:Antibacterialsforsystemicuse,macrolides,tilmicosin.

ATCvetcode:QJ01FA91

5.1.Pharmacodynamicproperties:

Tilmicosinisasemi-syntheticantibioticofthemacrolidegroup,andisbelievedtoaffectbacterialprotein

synthesis.Itisbacteriostaticbutathighconcentrationsitmaybebactericidal.

Tilmicosinhasanin-vitroantibacterialspectrumthatispredominantlyGram-positivewithactivity

againstcertainGram-negativemicro-organisms.ThespectrumincludesMannheimia,Pasteurella,

Actinobacillus(Haemophilus),Actinomyces(Corynebacterium),Fusobacterium,Dichelobacter,

Staphylococcus,andMycoplasmaorganismsofbovine,porcine,ovineandavianorigin.

Followingoralorparenteraladministrationoftilmicosinthemaintargetorganfortoxicityistheheart.

Theprimarycardiaceffectsareincreasedheartrate(tachycardia)anddecreasedcontractility(negative

inotrophy).Cardiovasculartoxicitymaybeduetocalciumchannelblockade.

Indogs,CaCl

2 treatmentshowedapositiveeffectontheleftventricularinotrophicstateaftertilmicosin

administrationandsomechangesinvascularbloodpressureandheartrate.

Dobutaminepartiallyoffsetthenegativeinotropiceffectsinducedbytilmicosinindogs.Betaadrenergic

antagonistssuchaspropanololexacerbatedthenegativeinotrophyoftilmicosinindogs.

Inpigs,intramuscularinjectionof10mgtilmicosin/kgcausedincreasedrespiration,emesisand

convulsions;20mg/kgresultedinmortalityin3of4pigs,and30mg/kgcausedthedeathofall4pigs

tested.Intravenousinjectionof4.5to5.6mgtilmicosin/kgfollowedbyintravenousinjectionof1ml

epinephrine(1/1000)2to6timesresultedindeathofall6injectedpigs.Pigsgiven4.5to5.6mg

tilmicosin/kgintravenouslywithnoepinephrineallsurvived.Theseresultssuggestthatintravenous

epinephrinemaybecontraindicated.

5.2.Pharmacokineticparticulars:

Absorption:Whenadministeredasrecommendedtocalvesandsheepbysubcutaneousinjectionoverthe

dorso-lateralchest,themainparametersare:

Doserate(tilmicosin) T

Cattle:

Neonatalcalves

Feedlotcattle

10mg/kgb.w.

10mg/kgb.w.

1hour

1hour

1.55µg/ml

0.97µg/ml

Sheep:

40kganimals

28-50kganimals

10mg/kgb.w.

10mg/kgb.w.

8hours

8hours

0.44µg/ml

1.18µg/ml

Distribution:Followingsubcutaneousinjection,tilmicosinisdistributedthroughoutthebody,but

especiallyhighlevelsarefoundinthelung.Incalves,lungconcentrationsoftilmicosinremainabovethe

of3.12µg/mlforMannheimiahaemolyticaforatleast72hoursafterinjection.Inlambs,lung

concentrationwasfoundtobeapproximately3.7µg/mlthreedaysafterasinglesubcutaneousinjectionof

10mg/kg.Inlactatingewes,milklevelsremainedabovetheMIC

of<1

g/mlforStaphylococcus

aureusforatleast72hoursafterinjection.

Biotransformation:Severalmetabolitesareformed,thepredominantonebeingidentifiedasT1(N-

demethyltilmicosin).Howeverthebulkofthetilmicosinisexcretedunchanged.

Elimination:Followingsubcutaneousinjection,tilmicosinisexcretedmainlyviathebileintothefaeces,

butasmallproportionisexcretedviatheurine.Thehalf-lifefollowingsubcutaneousinjectionincattleis

2-3days.

6.PHARMACEUTICALPARTICULARS

6.1.Listofexcipients:

Propyleneglycol

Phosphoricacid(forpHadjustment)

WaterforInjection

6.2.Incompatibilities:

Intheabsenceofcompatibilitystudies,thisveterinarymedicinalproductmustnotbemixedwithother

veterinarymedicinalproducts.

6.3.Shelf-life:

Shelf-lifeoftheveterinarymedicinalproductaspackagedforsale:3years.

Shelf-lifeafterfirstopeningtheimmediatepackaging:28days.

6.4.Specialprecautionsforstorage:

Donotstoreabove25°C.Protectfromlight.

Onceopenedusetheremainingsolutionwithin28 days.Discardunusedmaterial.

6.5.Natureandcompositionofimmediatepackaging:

Cardboardboxwith1or12multi-doseambercoloured,glassvials(typeII)of50or100mlwith

bromobutyl,teflon-coatedstoppersandanaluminiumcap.

Notallpacksizesmaybemarketed.

6.6.Specialprecautionsforthedisposalofunusedveterinarymedicinalproduct

orwastematerialsderivedfromtheuseofsuchproducts:

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuchveterinarymedicinal

productsshouldbedisposedofinaccordancewithlocalrequirements.

7.MARKETINGAUTHORISATIONHOLDER

EMDOKAbvba,JohnLijsenstraat,16,B-2321Hoogstraten,Belgium.

8.MARKETINGAUTHORISATIONNUMBER:……

9.DATEOFFIRSTAUTHORISATION/RENEWALOFTHEAUTHORISATION:………

10.DATEOFREVISIONOFTEXT:………

PROHIBITIONOFSALE,SUPPLYAND/ORUSE:

[TobecompletedinaccordancewithnationalrequirementsafterconclusionoftheDCphase,e.g.:]

<Prescriptiononlymedicine.>

<Forusebyveterinarysurgeonsonly.>

30-10-2018

Sciegen Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Irbesartan Tablets, USP  75 Mg, 150 Mg, and 300 Mg Due to The Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in The Active Pharmaceutical Ingredient (API)

Sciegen Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Irbesartan Tablets, USP 75 Mg, 150 Mg, and 300 Mg Due to The Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in The Active Pharmaceutical Ingredient (API)

ScieGen Pharmaceuticals, Inc. is voluntarily recalling listed lots, within expiry, of Irbesartan Tablets, USP 75 mg, 150 mg, and 300 mg dosage forms to the consumer level. These products are being recalled due to the presence of an impurity, N-nitrosodiethylamine (NDEA) contained in the API Irbesartan, USP manufactured by Aurobindo Pharma Limited. This impurity, which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, has been classified as a...

FDA - U.S. Food and Drug Administration

12-9-2018

FDA takes new steps to address epidemic of youth e-cigarette use, including a historic action against more than 1,300 retailers and 5 major manufacturers for their roles perpetuating youth access

FDA takes new steps to address epidemic of youth e-cigarette use, including a historic action against more than 1,300 retailers and 5 major manufacturers for their roles perpetuating youth access

FDA takes new steps to address epidemic of youth e-cigarette use, including a historic action against more than 1,300 retailers and 5 major manufacturers for their roles perpetuating youth access

FDA - U.S. Food and Drug Administration

19-7-2018

Openfoodtox: over 300 substances added to EFSA chemical hazards database

Openfoodtox: over 300 substances added to EFSA chemical hazards database

Openfoodtox: over 300 substances added to EFSA chemical hazards database

Europe - EFSA - European Food Safety Authority Press Releases & News Stories

17-3-2017

Withdrawal of a batch of EpiPen® 300 micrograms

Withdrawal of a batch of EpiPen® 300 micrograms

MEDA recalls a batch of the adrenaline product EpiPen® 300 micrograms/dose, which is used for sudden allergic reactions. There is a risk that the auto-injector does not work. The withdrawal concerns product number 578818 with batch number: 5FA665B and expiry date 03/2017.

Danish Medicines Agency

21-2-2017

Takeda Pharma A/S recalls batch of Pamol® in packs of 300 film-coated tablets

Takeda Pharma A/S recalls batch of Pamol® in packs of 300 film-coated tablets

Takeda Pharma A/S recalls a batch of Pamol® in packs of 300 film-coated tablets after the discovery of Ibumetin 600 mg containing ibuprofen in some packs. Both types of medicine are used for the treatment of mild pain, but they work in different ways and may cause different adverse reactions.

Danish Medicines Agency

There are no news related to this product.